medigraphic.com
ISSN 1561-2988 (Print)

2015, Number 1

<< Back Next >>

Rev Cubana Farm 2015; 49 (1)

Release of pravastine sodium formulated in polymer Chitosan/Pluronic F-127 matrices

Serrano CP, Guadarrama EOR, Escobar CJJ, Melgoza CLM, López AR, Revilla VAL

Language: Spanish
References: 32
Page: 18-28
PDF size: 260.24 Kb.


ABSTRACT

Introduction: the development of transdermal drugs has aroused great interest in recent years due to their advantages, however many of the drug delivery systems use soluble matrix components which could trigger therapeutic problems due to a rapid release of the active ingredient. Therefore, insoluble polymers are being tested that can modulate the release of a pharmaceutically active ingredient.
Objective: to evaluate the release of pravastatin sodium in insoluble polymer chitosan/PF-127 matrices by VER to obtain kinetic profile of release in order to submit them as viable systems for the manufacture of transdermal patches.
Methods: studies on the chemical content, diameter and thickness of films, differential scanning calorimetry and release studies were performed. The UV-Vis spectrophotometry at 238 nm allowed quantitating the active principle.
Results: transdermal patches with adequate uniform drug content, suitable thickness and diameter with good stability, based on calorimetric studies, were obtained. The use of PF-127 increased or delayed the release of pravastatin sodium from the polymeric matrix depending on concentration. When performing the kinetic profiles of release, the formulations were regulated to zero kinetic that describes the behavior of some transdernal systems.
Conclusions: the results demonstrated the possibility of using these insoluble polymer chitosan/PF-127 matrices to modulate the release of pravastin sodium and of other structurally similar drugs, thus creating new alternatives to existing pharmaceutical oral forms for treatment of diseases.


REFERENCES

  1. Ghosh K, Pfister F. Transdermal and Topical Delivery Systems: An overview and future trends. Florida: CRC Press; 1997;p.1-32.

  2. Ling A, Shearwood C, Chye K, Lua J, Moochhala S. Transdermal microneedles for drug delivery applications. Mat Sci Eng B. 2006;132:151–154.

  3. Flores Peña S. La electroporación: Método físico para la penetración transdérmica de fármacos. [Tesis de Licenciatura]. Asesor: Dr. José Juan Escobar Chávez. Cuautitlán Izcalli, Estado de México: FESC UNAM; 2010.

  4. Hock S, William R. Pfister. Pressure-sensitive adhesives for transdermal drug delivery systems. Pharm Sci Technol. 1999;2(2):60-69.

  5. Donatas S. Handbook of pressure sensitive adhesive technology 1. Michigan, USA, Satas & Associates;1999;p.36-61.

  6. Mycek J, Harvey R, Champe P. Farmacología. 2 ed. México: McGraw-Hill Interamericana; 2007, p.247-256.

  7. Ramírez E, Laosa O, Guerra P, Duque B, Mosquera B, Borobia A, Lei S, Carcas A, Frias J. Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic ClassificationSystem.Br J Clin Pharmacol. 2010; 70(5):694-702.

  8. Escobar Chávez JJ, López Cervantes M, Naïk A, Quintanar Guerrero D, Ganem Quintanar A. Applications of thermoreversible pluronic F-127 gels in Pharmaceutical Formulations. J Pharm Pharmaceut Sci. 2006;9(3):339-358.

  9. Almeida H, Amaral H, Lobão P. Temperature and pH stimuli-responsive polymers and their applications in controlled and selfregulated drug delivery. JAPS. 2012;02(06):1-10.

  10. Serrano Castañeda P, Escobar Chávez JJ, Morales Hipólito E, Domínguez Delgado C, Abrego Reyes H. Microagujas y Transcutol® como promotores de la penetración transdérmica de sibutramina formulada en parche transdérmico. Rev Cubana Farm. 2013;47(3).

  11. Sigma Aldrich 2012. [citado 07 Oct 2012]; Disponible en: http://www.sigmaaldrich.com/catalog/product/sigma/16758?lang=es®ion

  12. Okuyama K, Noguchi K, Kanenari M, Egawa T, Osawa K, Ogawa K. Structural diversities of chitosan and its complexes. Carbohydr Polym. 2000;41(3):237-247.

  13. Malette W, Quigley H, Adickes E. In Chitin in Nature and Technology. New York, USA, Plenum Press;1986,p.435–442.

  14. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res. 1998;15:1326-1331.

  15. Shu X, Zhu K. A novel approach to prepare tripolyphosphate/chitosan complex beads for controlled release drug delivery. Int J Pharm. 2000;201:51-58.

  16. Escobar Chávez JJ, Merino V,Díez Sales O,Nácher Alonso A, Ganem Quintanar A, Herráez Merino Sanjuán M. Transdermal nortriptyline hydrocloride patch formulated within a chitosan matrix intended to be used for smoking cessation. Pharm Dev Technol. 2011;16(2):162-169.

  17. López Cervantes M, Escobar Chávez JJ, Casas Alancaster N, Quintanar Guerrero D, Ganem Quintanar A. Development and characterization of a transdermal patch and an emulgel containing kanamycin intended to be used in the treatment of mycetoma caused by Actinomadura madurae. Drug Dev Ind Pharm. 2009; 35(12):1511-1521.

  18. Lakshmana P, Shirwaikar A, Shirwaikar A, Jacob A. Design and Evaluation of Matrix Diffusion Controlled Transdermal Patches of Diltiazem Hydrochloride. Ars Pharm. 2008;49(3):211-227.

  19. Gennaro A. Remington Farmacia. 20ª. Ed. México: Panamericana; 2000.

  20. Serrano Castañeda P. Desarrollo y caracterización de un parche transdérmico de pravastatina acoplado a microagujas como promotor físico de la penetración transdérmica [Tesis de Maestría]. México D.F: UAM Xochimilco;2013.

  21. Lakshmana P, Shirwaikar A, Shirwaikar A, Jacob A. Design and Evaluation of Matrix Diffusion Controlled Transdermal Patches of Diltiazem Hydrochloride. Ars Pharm. 2008;49(3):211-227.

  22. Zeng M, Fang Z, Xu C. Effect of compatibility on the structure of the microporous membrane prepared by selective dissolution of chitosan/synthetic polymer blend membrane. J Membr Sci. 2004;230:175-181.

  23. Esam A, Elham S, Azizah M, Abdul H. Characterization of chitosan in acetic acid: Rheological and thermal studies. Turk J Chem. 2010;34:47-56.

  24. Tripathi S, Mehrotra G, Dutta P. Physicochemical and bioactivity of cross-linked chitosan–PVA film for food packaging applications. Int J Biol Macromol. 2009;45:372-376.

  25. Yogesh G, Kamla P. Design and In Vitro Performance Evaluation of Purified Microparticles of Pravastatin Sodium for Intestinal Delivery. Pharm Sci Tech. 2011;12(2):673-682.

  26. Keri V, Nagyne A, Czovek H, Mezei K, Katai I, Racz C. Methods of making pravastatin sodium. US. US20060194984A1. 2006 aug 31.

  27. Kima I, Yoo M, Kima B, Kimb S, Lee H, Choa C. Preparation of semiinterpenetrating polymer networks composed of chitosan and poloxamer. Int J Biol Macromol. 2006;38:51-58.

  28. Yu K. Devising a Protein Formulation Strategy. Genet Eng Biotechn N. 2012;32(16):38-40.

  29. Aulton ME. Pharmaceutics The Science of Dosage Form Design. 2ª Ed.: London. Churchill Livingstone; 2001.

  30. Chunga T, Lind S, Liub D, Tyanc Y, Yanga J. Sustained release of 5-FU from Poloxamer gels interpenetrated by crosslinking chitosan network. Int J Pharm. 2009;238:39-44.

  31. Elham K, Mohsen T, Fariba G, Khalil A, Hanie N. In vitro Insulin Release from Thermosensitive Chitosan Hydrogel. AAPS Pharm Sci Tech. 2012;13(2):460-466.

  32. Costa P, Sousa J. Modeling and comparison of dissolution profiles. EUR J PharmSci. 2001;13:123-133.




2020     |     www.medigraphic.com